-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30

Benzinga·10/27/2026 13:29:46
Listen to the news
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $18 to $30.